Perspective on current and emerging drugs in the treatment of acute and chronic toxoplasmosis

References

• Ben-Harari RR, Connolly MP. High burden and low awareness of toxoplasmosis in the United States. Postgrad Med. 2019;131:103–108.
   PubMed Web of Science ®Google Scholar
• WHO: World Health Organization. WHO library cataloguing-in-publication data: neglected tropical diseases, hidden successes, emerging opportunities. WHO/HTM/NTD/2009.2». 1 Tropical medicine World Health Organization; 2009. ISBN 978 92 4 159870 5 (NLM classi?cation: WC 680). Available from: https://apps.who.int/iris/bitstream/handle/10665/44214/9789241598705_eng.pdf;sequence=1
   Google Scholar
• CDC (Centers for Disease Control). Toxoplasmosis: neglected parasitic infections of the United States; [ cited 2018 April]. Available from: https://www.cdc.gov/parasites/toxoplasmosis/index.html
   Google Scholar
• Jones JL, Parise ME, Fiore AE. Neglected parasitic infections in the United States: toxoplasmosis. Am J Trop Med Hyg. 2014 May 7;90(5):794–799.
   PubMed Web of Science ®Google Scholar
• Batz M, Hoffmann S, Morris JG Jr. Disease-outcome trees, EQ-5D scores, and estimated annual losses of quality-adjusted life years (QALYs) for 14 foodborne pathogens in the United States. Foodborne Pathog Dis. 2014 May;11(5):395–402.
   PubMed Web of Science ®Google Scholar
• Jones JL, Dubey JP. Foodborne toxoplasmosis. Clinl Infect Dis. 2012;55(6):845–851.
   PubMed Web of Science ®Google Scholar
• Jones JL, Roberts JM. Toxoplasmosis hospitalizations in the United States, 2008, and trends, 1993–2008. Clin Infect Dis. 2012 Apr;54(7):e58–61.
   PubMed Web of Science ®Google Scholar
• Scallan E, Hoekstra RM, Angulo FJ, et al. Foodborne illness acquired in the United States—Major pathogens. EID. 2011;17(1):7–15.
   PubMed Web of Science ®Google Scholar
• Montoya JG, Boothroyd JC, Kovacs JA. Toxoplasma gondii. In: Gerald M, Bennett JE, Dolin R, editors. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. 7th ed. Philadelphia, PA: Churchill Livingstone Elsevier; 2015. p. 3122–3153.
   Google Scholar
• JL J, GN H. Short report: annual burden of ocular toxoplasmosis in the United States. Am J Trop Med Hyg. 2010;82(3):464 465.
   PubMed Web of Science ®Google Scholar
• Konstantinovic N, Guegan H, Stäjner T, et al. Treatment toxoplasmosis: current options and future perspectives. Food Waterborne Parasitol. 2019;15:e00036. in press.
   PubMedGoogle Scholar
• McAuley JB. Congenital toxoplasmosis. J Pediatr Infect Dis Soc. 2014;3(Suppl 1):S30–S35.
   PubMedGoogle Scholar
• Kieffer F, Wallon M. Congenital toxoplasmosis. Handb Clin Neurol. 2013;112:1099–1101.
   PubMedGoogle Scholar
• Belk K, Connolly MP, Schlesinger L, et al. Patient and treatment pathways for toxoplasmosis in the United States: data analysis of the vizient health systems data from 2011 to 2017. Pathog Glob Health. 2018;112:428–437.
   PubMed Web of Science ®Google Scholar
• Maldonado YA, Read JS, COMMITTEE ON INFECTIOUS DISEASES. Diagnosis, treatment, and prevention of congenital toxoplasmosis in the United States. Pediatrics. 2017;139:e20163860.
   PubMed Web of Science ®Google Scholar
• Montoya JG, Boothroyd JC, Kovacs JA. Toxoplasma gondii in Mandell Douglas, and Bennett’s principles and practice of infectious diseases. 8th. GL M, JE B, Dolin R, editors. Churchill Philadelphia: Livingstone Elsevier; 2105.
   Google Scholar
• de-la-Torre A, Stanford M, Curi A, et al. Therapy for ocular toxoplasmosis. Ocul Immunol Inflamm. 2011 Oct;19(5):314–320.
   PubMed Web of Science ®Google Scholar
• Montoya JG, Liesenfeld O. Toxoplasmosis. Lancet. 2004;363: 1965–1976. Stanford M, Curi A, Jaffe GJ, Gomez-Marin JE. 2011. Therapy for ocular toxoplasmosis. Ocul Immunol Inflamm.;19:314–320.
   PubMed Web of Science ®Google Scholar
• Montoya JG, Remington JS. Management of Toxoplasma gondii infection during pregnancy. Clin Infect Dis. 2008;47:554–566.
   PubMed Web of Science ®Google Scholar
• Van der Ven AJAM, Schoondermark-van de Ven EME, Camps WIL, et al. Anti-toxoplasma effect of pyrimethamine, trimethoprim and sulphonamides alone and in combination: implications for therapy. J Antimicrobial Chemother. 1996;38:75–80.
   PubMed Web of Science ®Google Scholar
• Allegra CJ, Boorman D, Kovacs JA, et al. Interaction of sulfonamide and sulfone compounds with toxoplasma gondii dihydropteroate synthase. J Clin Invest. 1990;85:371–379.
   PubMed Web of Science ®Google Scholar
• Anderson AC. Targeting DHFR in parasitic protozoa. Drug Discov Today. 2005;10:121–128.
   PubMed Web of Science ®Google Scholar
• Sharma M, Chauhan PMS. Dihydrofolate reductase as a therapeutic target for infectious diseases: opportunities and challenges. Future Med Chem. 2012 Jul 16;4(10): Review. Published Online. DOI:10.4155/fmc.12.68
   Web of Science ®Google Scholar
• Yun M-K, Wu Y, Li Z, et al. Catalysis and sulfa drug resistance in dihydropteroate synthase: crystal structures reveal the catalytic mechanism of DHPS and the structural basis of sulfa drug action and resistance. Science. 2012 March 2;335(6072):1110–1114.
   PubMed Web of Science ®Google Scholar
• Ben-Harari RR, Goodwin E, Casoy J. Adverse event profile of pyrimethamine-based therapy in toxoplasmosis: a systematic review. Drugs R D. 2017;1–22.
   PubMed Web of Science ®Google Scholar
• Frenkel JK, Weber RW, Lunde MN. Acute toxoplasmosis: effective treatment with pyrimethamine, sulfadiazine, leucovorin calcium and yeast. JAMA. 1960;173:1471–1476.
   PubMed Web of Science ®Google Scholar
• Freund YR, Dabbs J, Creek MR, et al. Synergistic bone marrow toxicity of pyrimethamine and zidovudine in murine in vivo and in vitro models: mechanism of toxicity. Toxicol Appl Pharmacol. 2002;181:16–26.
   PubMed Web of Science ®Google Scholar
• Visentin M, Zhao R, Goldman DI. The antifolates. Hematol Oncol Clin North Am. 2012 June;26(3):629–652.
   PubMed Web of Science ®Google Scholar
• Macy E, Poon K-YT. Self-reported antibiotic allergy incidence and prevalence: age and sex effects. Am J Med. 2009;122:778.e1–7.
   PubMed Web of Science ®Google Scholar
• Wulf NR, Matuszewski KA. Sulfonamide cross-reactivity: is there evidence to support broad cross-allergenicity? Am J Health Syst Pharm. 2013;70:1483–1494.
   PubMed Web of Science ®Google Scholar
• Connolly MP, Haitsma G, Hernández AV, et al. Systematic review and meta-analysis of secondary prophylaxis for prevention of HIV-related toxoplasmic encephalitis relapse using trimethoprim-sulfamethoxazole. Pathog Glob Health. 2017a;111:327–331.
   PubMed Web of Science ®Google Scholar
• Connolly MP, Goodwin E, Schey C, et al. Toxoplasmic encephalitis relapse rates with pyrimethamine-based therapy: systematic review and meta-analysis. Pathog Glob Health. 2017b;111:31–44.
   PubMed Web of Science ®Google Scholar
• Alday PH, Doggett JS. Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug Des Dev Ther. 2017;11:273–293.
   PubMed Web of Science ®Google Scholar
• Hopper AT, Brockman A, Wise A, et al. Discovery of selective Toxoplasma gondii dihydrofolate reductase inhibitors for the treatment of toxoplasmosis. J Med Chem. 2019;2019(62):1562–1576.
   Web of Science ®Google Scholar
• Doggett JS, Nilsen A, Forquer I, et al. Endochin-like quinolones are highly efficacious against acute and latent experimental toxoplasmosis. Proc Natl Acad Sci U S A. 2012;109:15936–15941.
   PubMed Web of Science ®Google Scholar
• Antczak M, Dzitko K, Dlugonska H. Review human toxoplasmosis – searching for novel chemotherapeutics. Biomed Pharmacother. 2016;82:677–684.
   PubMed Web of Science ®Google Scholar
• McFarland MM, Zach SJ, Wang X, et al. Review of experimental compounds demonstrating anti-Toxoplasma activity. Antimicrob Agents Chemother. 2016;60:7017–7034.
   PubMed Web of Science ®Google Scholar
• Murata Y, Sugi T, Weiss LM, et al. Identification of compounds that suppress Toxoplasma gondii tachyzoites and bradyzoites: research article. PLoS ONE. 2017;12(6):e0178203.
   PubMed Web of Science ®Google Scholar
• Mui EJ, Schiehser GA, Milhous WK, et al. Novel Triazine JPC-2067-B inhibits Toxoplasma gondii in vitro and in vivo. PLoS Negl Trop Dis. 2008;2(3):e190.
   PubMed Web of Science ®Google Scholar
• Welsch ME, Zhou J, Gao Y, et al. Discovery of potent and selective leads against Toxoplasma gondii dihydrofolate reductase via structure-based design. ACS Med Chem Lett. 2016;7(12):1124–1129.
   PubMed Web of Science ®Google Scholar
• Gangjee A, Adair OO, Pagley M, et al. N9-substituted 2,4-diaminoquinazolines: synthesis and biological evaluation of lipophilic inhibitors of pneumocystis carinii and Toxoplasma gondii dihydrofolate reductase. J Med Chem. 2008;51:6195–6200.
   PubMed Web of Science ®Google Scholar
• Gangjee A, Lin X, Biondo LR, et al. CoMFA analysis of tgDHFR and rlDHFR based on antifolates with 6-5 fused ring system using the all-orientation search (AOS) routine and a modified cross validated r2-guided region selection (q2-GRS) routine and its initial application. Bioorg Med Chem. 2010;18:1684–1701.
   PubMed Web of Science ®Google Scholar
• Bag S, Tawari NR, Degani MS, et al. Design, synthesis, biological evaluation and computational investigation of novel inhibitors of dihydrofolate reductase of opportunistic pathogens. Bioorg Med Chem. 2010;18:3187–3197.
   PubMed Web of Science ®Google Scholar
• Chio LC, Queener SF. Identification of highly potent and selective inhibitors of Toxoplasma gondii dihydrofolate reductase. Antimicrob Agents Chemother. 1993;37:1914–1923.
   PubMed Web of Science ®Google Scholar
• Piper JR, Johnson CA, Krauth CA, et al. Lipophilic antifolates as agents against opportunistic infections. 1. Agents superior to trimetrexate and piritrexim against Toxoplasma gondii and pneumocystis carinii in in vitro evaluations. J Med Chem. 1996;39:1271–1280.
   PubMed Web of Science ®Google Scholar
• Rosowsky A, Cody V, Galitsky N, et al. Structure-based design of selective inhibitors of dihydrofolate reductase: synthesis and antiparasitic activity of 2,4-diaminopteridine analogues with a bridged diarylamine side chain. J Med Chem. 1999;42:4853–4860.
   PubMed Web of Science ®Google Scholar
• Montazeri M, Mehrzadi S, Mehdi S, et al. Activities of anti-toxoplasma drugs and compounds against tissue cysts in the last three decades (1987 to 2017), a systematic review. Parasitol Res. 2018;117:3045.
   PubMed Web of Science ®Google Scholar
• Zwicker JD, Diaz NA, Guerra AJ, et al. Optimization of dipeptidic inhibitors of cathepsin L for improved Toxoplasma gondii selectivity and CNS permeability. Bioorg Med Chem Lett. 2018;28:1972–1980.
   PubMed Web of Science ®Google Scholar
• Lourido S, Shuman J, Zhang C, et al. Calcium-dependent protein kinase 1 is an essential regulator of exocytosis in toxoplasma. Nature. 2010;465:359–362.
   PubMed Web of Science ®Google Scholar
• Sugi T, Kato K, Kobayashi K, et al. Use of the kinase inhibitor analog 1NM-PP1 reveals a role for Toxoplasma gondii CDPK1 in the invasion step. Eukaryot Cell. 2010;9:667–670.
   PubMed Web of Science ®Google Scholar
• Child MA, Garland M, Foe I, et al. Toxoplasma DJ-1 regulates organelle secretion by a direct interaction with calcium-dependent protein kinase 1. mBio. 2017;8:e02189–16. https://doi.org/10.1128/mBio.02189-16
   PubMed Web of Science ®Google Scholar
• Long S, Wang Q, Sibley LD. Analysis of noncanonical calcium dependent protein kinases in Toxoplasma gondii by targeted gene deletion using CRISPR/Cas9. Infect Immun. 2019;84:1262–1273.
   Web of Science ®Google Scholar
• Cardew EM, Verlinde CLMJ, Pohl E. The calcium-dependent protein kinase 1 from Toxoplasma gondii as target for structure-based drug design. Parasitology. 2018;145:210–218.
   PubMed Web of Science ®Google Scholar
• Ojo KK, Larson ET, Keyloun KR, et al. Toxoplasma gondii calcium-dependent protein kinase 1 inhibitor. Nat Struct Mol Biol. 2010;17:602–607.
   PubMed Web of Science ®Google Scholar
• Moine E, Dimier-Poisson I, Enguehard-Gueiffier C, et al. Development of new highly potent imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1. Europ J Med Chem. 2015a;105:80–105.
   PubMed Web of Science ®Google Scholar
• Moine E, Denevault-Sabourin C, Debierre-Grockiego F, et al. A small-molecule cell-based screen led to the identification of biphenylimidazoazines with highly potent and broad-spectrum anti-apicomplexan activity. Europ J Med Chem. 2015b;9:386–400.
   Web of Science ®Google Scholar
• Moine E, Moiré N, Dimier-Poisson I, et al. Imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1 decrease the parasite burden in mice with acute toxoplasmosis. Int J Parasitol. 2018;48:561–568.
   PubMed Web of Science ®Google Scholar
• Hui R, El Bakkouri M, Sibley LD. Designing selective inhibitors for calcium-dependent protein kinases in apicomplexans. Trends Pharmacol Sci. 2015;36:452–460.
   PubMed Web of Science ®Google Scholar
• Rutaganira FU, Barks J, Dhason MS, et al. Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by toxoplasma gondii. J Med Chem. 2017;60:9976–9989.
   PubMed Web of Science ®Google Scholar
• Huang W, Ojo KK, Zhang Z, et al. SAR studies of 5-aminopyrazole-4-carboxamide analogues as potent and selective inhibitors of Toxoplasma gondii CDPK1. ACS Med Chem Lett. 2015;6:1184–1189.
   PubMed Web of Science ®Google Scholar
• Doggett JS, Ojo KK, Fan E, et al. Bump Kinase Inhibitor 1294 treats established Toxoplasmosis gondii infection. Antimicrob Agents Chemother. 2014 June;58(6):3547–3549.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ojo KK, Johnson SM, et al. Benzoylbenzimidazole-based selective inhibitors targeting Cryptosporidium parvum and Toxoplasma gondii calcium-dependent protein kinase-1. Bioorg Med Chem Lett. 2012;22:5264–5267.
   PubMed Web of Science ®Google Scholar
• Lourido S, Zhang C, Lopez MS, et al. Optimizing small molecule inhibitors of calcium-dependent protein kinase 1 to prevent infection by Toxoplasma gondii. J Med Chem. 2013;56(7):3068–3077.
   PubMed Web of Science ®Google Scholar
• Murphy RC, Ojo KK, Larson ET, et al. Discovery of potent and selective inhibitors of CDPK1 from C. parvum and T. gondii. ACS Med Chem Lett. 2010;1:331–335.
   PubMed Web of Science ®Google Scholar
• Johnson SM, Murphy RC, Geiger JA, et al. Development of Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitors with potent anti-toxoplasma activity. J Med Chem. 2012;55:2416–2426.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Ojo KK, Vidadala R, et al. The apicomplexan plastid and its evolution. CMLS. 2011;68:1285–1296.
   PubMed Web of Science ®Google Scholar
• Vidadala RS, Rivas KL, Ojo KK, et al. Development of an orally available and central nervous system (CNS) penetrant Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitor with minimal human ether-a-go-go-related gene (hERG) activity for the treatment of toxoplasmosis. J Med Chem. 2016;59:6531–6546.
   PubMed Web of Science ®Google Scholar
• Hulverson MA, Vinayak S, Choi R, et al. Bumped-kinase inhibitors for cryptosporidiosis therapy. J Infect Dis. 2017;215(8):1275–1284.
   PubMed Web of Science ®Google Scholar
• CDC: Resource for health professionals, diagnosis and treatment guidelines for toxoplasmosis; [ cited 2019 April]. Available from: https://www.cdc.gov/parasites/toxoplasmosis/health_professionals/index.html.
   Google Scholar
• Department of Health and Human Services (USA). AIDsInfo, guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV; [ cited 2019 April]. Available from: https://aidsinfo.nih.gov/guidelines/html/4/adult-and-adolescent-opportunistic-infection/322/toxo
   Google Scholar
• Brown AS. Further evidence of infectious insults in the pathogenesis and pathophysiology of schizophrenia. Am J Psychiatry. 2011;168:764–766.
   PubMed Web of Science ®Google Scholar
• REVIEW: FJ. Influence of latent Toxoplasma infection on human personality, physiology and morphology: pros and cons of the Toxoplasma–human model in studying the manipulation hypothesis. J Exp Biol. 2013;216:127–133.
   PubMed Web of Science ®Google Scholar
• Flegr J. Schizophrenia and Toxoplasma gondii: an undervalued association? Expert Rev Anti Infect Ther. 2015;13:817–820.
   PubMed Web of Science ®Google Scholar
• Sutterland AL, Fond G, Kuin A, et al. Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand. 2015;132:161–179.
   PubMed Web of Science ®Google Scholar
• Jeffers V, Tampaki Z, Kim K, et al. A latent ability to persist: differentiation in Toxoplasma gondii. Cell Mol Life Sci. 2018;75:2355–2373.
   PubMed Web of Science ®Google Scholar